Efficacy and safety of trastuzumab plus different chemotherapy regimens in treatment of the patients with HER-2-positive advanced breast cancer.
- Author:
Jihong GUO
1
;
Binghe XU
2
;
Fei MA
1
;
Ying FAN
1
;
Peng YUAN
1
;
Jiayu WANG
1
;
Ruigang CAI
1
;
Qing LI
1
;
Pin ZHANG
1
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Antibodies, Monoclonal, Humanized; adverse effects; therapeutic use; Antineoplastic Combined Chemotherapy Protocols; adverse effects; therapeutic use; Breast Neoplasms; drug therapy; metabolism; pathology; Carcinoma, Ductal, Breast; drug therapy; metabolism; pathology; Disease Progression; Disease-Free Survival; Female; Fever; chemically induced; Follow-Up Studies; Humans; Middle Aged; Neoplasm Grading; Neutropenia; chemically induced; Receptor, ErbB-2; metabolism; Remission Induction; Retrospective Studies; Survival Rate; Taxoids; administration & dosage; Trastuzumab; Vinblastine; administration & dosage; analogs & derivatives; Vomiting; chemically induced
- From: Chinese Journal of Oncology 2014;36(5):372-376
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo evaluate the efficacy and safety of trastuzumab plus different chemotherapy regimens in treatment of patients with HER-2-positive advanced breast cancer.
METHODS132 patients with advanced HER-2-positive breast cancer were treated with trastuzumab plus different regimens. The clinical characteristics, efficacy and toxicity of the 132 patients were retrospectively analyzed.
RESULTSFive patients had complete response (CR), 61 patients had partial response (PR), 39 patients had stable disease (SD), and 27 patients had progressive disease (PD). The objective response rate was 50.0% and the disease control rate was 79.5%. The median progression-free survival was 9.3 months. The median overall survival time was 46.2 months. The 1-, 2-, 5- year survival rates were 98.3%, 81.9% and 40.2%, respectively. Trastuzumab combined with chemotherapy is superior to trastuzumab monotherapy (51.2% vs. 33.3%). The number of metastatic sites, efficacy, different previous treatment lines were independent prognostic factors of PFS (P = 0.002, P < 0.0001 and P < 0.0001, respectively). Visceral metastases, pathological grade, and PFS were independent prognostic factors of OS (P = 0.041, P = 0.001, P = 0.025, P < 0.001, P < 0.0001 and P < 0.0001, respectively). Regarding the toxicities, one case discontinued treatment due to the decrease of left ventricular ejection fraction to 47%, two cases had heartbeat tachycardia, 6 cases had palpitation, 17 cases had a fever during first input trastuzumab. No other serious cardiac toxicity was observed. The most common toxicities were chemotherapy-related hematological and non-hematological toxicities.
CONCLUSIONSTrastuzumab combined with chemotherapy is superior to trastuzumab monotherapy. Patients may get benefits for early use of trastuzumab. Trastuzumab plus chemotherapy is effective and well tolerated in patients with advanced HER-2 positive breast cancer. No heart failure occurred in this series of patients, and cardiac safety seems better than that in Caucasians because of younger age at the onset in Chinese advanced breast cancer patients.
